Navigation Links
Palatin Technologies, Inc. Reports Third Quarter Fiscal Year 2011 Results
Date:5/16/2011

er Palatin's research collaboration and license and clinical trial collaboration agreements with AstraZeneca as a result of the successful completion of the research collaboration portion of the agreements, and secondarily to a non-cash, non-operating expense of $1.3 million, which represents the increase in estimated fair value of the warrant liability.  

RevenueFor the quarter ended March 31, 2011, Palatin recognized $0.1 million of contract revenue under its license and collaboration agreement with AstraZeneca, compared to $2.6 million for the same period in 2010.

Costs and ExpensesTotal operating expenses for the quarter ended March 31, 2011 were $2.7 million compared to $4.6 million for the comparable quarter of 2010.  The net decrease in operating expenses for the quarter was primarily due to Palatin's previously disclosed realignment of resources and reduction in staffing levels in 2010.

Cash positionPalatin's cash and cash equivalents were $22.0 million as of March 31, 2011, compared to cash, cash equivalents and investments of $8.9 million at June 30, 2010, with current liabilities of $1.9 million as of March 31, 2011 compared to $2.4 million as of June 30, 2010.  

The increase in cash and cash equivalents is attributable to Palatin's previously announced completion of its $23.0 million public offering in which Palatin sold 23,000,000 shares of its common stock, Series A warrants to purchase up to 2,000,000 shares of its common stock, and Series B warrants to purchase up to 21,000,000 shares of its common stock.  The net proceeds to Palatin, after deducting underwriting discounts and commissions and other offering expenses, were approximately $21.1 million.  

The Company believes, based on its current operating plan, that its cash and cash equivalents as of March 31, 2011 will be sufficient to fund its operations through at least calendar year 2012.

CONFERENCE CALL / WEBCAST Pala
'/>"/>

SOURCE Palatin Technologies, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Palatin Technologies, Inc. Reports Positive Results of Phase 2a Clinical Study with PL-3994 for the Treatment of Heart Failure
2. Palatin Technologies, Inc. Revised Call-In Number for Teleconference and Webcast to be held on September 30, 2008
3. Palatin Technologies to Report Fiscal Year 2009 First Quarter Results; Conference Call and Webcast on November 17, 2008
4. Palatin Technologies Receives Notification Letter from NYSE Alternext US
5. Palatin Technologies to Report Fiscal Year 2009 Second Quarter Results; Conference Call and Webcast on February 17, 2009
6. Palatin Technologies Listing Compliance Plan Accepted by NYSE Alternext US
7. Palatin Technologies, Inc. Receives U.S. Patent Allowance for Heart Failure Drug Candidate
8. Palatin Technologies, Inc. Reports Positive Bremelanotide Study; Improved Safety Profile with Subcutaneous Administration
9. Palatin Technologies, Inc. to Raise $3.1 Million in Registered Direct Offering
10. Palatin Technologies to Present at the Rodman & Renshaw 11th Annual Global Investment Conference
11. Palatin Technologies, Inc. to Report Fourth Quarter and Fiscal Year 2009 Results; Teleconference and Webcast to be held on September 8, 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... Aug. 3, 2015  MiMedx Group, Inc. (NASDAQ: ... amniotic tissue and patent-protected processes to develop and market ... Orthopedic, Spine, Sports Medicine, Ophthalmic and Dental sectors of ... 35 th Annual Canaccord|Genuity Growth Conference in ... Chairman and CEO, William C. Taylor , President ...
(Date:8/3/2015)... Aug. 3, 2015  Aethlon Medical, Inc. (Nasdaq: AEMD ... treat life-threatening diseases, today announced that it will host ... webcast on Thursday, August 13, 2015 at 4:30 p.m. ... follow the release of fiscal 2016 first quarter results.  ... approximately two hours after the call at the Investor ...
(Date:8/3/2015)... Aug. 3, 2015 /PRNewswire/ - RepliCel Life Sciences Inc. (TSX.V: ... on the development of autologous cell therapies, announced today that ... the InvestMNT conference held in Minneapolis, Minnesota ... time. Hall,s presentation will highlight RepliCel,s 18-month milestones including CE ... Europe , clinical data from both RCT-01 (tendon) ...
(Date:7/31/2015)... , July 31, 2015 China Cord ... China,s leading provider of cord blood ... cell storage services, today announced that the Company has ... U.S. Securities and Exchange Commission. The filed Form 20-F ... March 31, 2015. The Form 20-F can be accessed ...
Breaking Biology Technology:MiMedx To Present At 35th Annual Canaccord|Genuity Growth Conference 2Aethlon Medical To Host First Quarter Fiscal 2016 Investor Call on August 13, 2015 2RepliCel Presenting at InvestMNT Investor Conference in Minneapolis 2China Cord Blood Corporation Files Its Annual Report on Form 20-F 2
... ... ... Xybion Corporation announced today that it has completed the acquisition of substantially all of ... The terms of the transactions were not disclosed., , ,Stelex and Vital-Path, based in Bensalem, ...
... CHENGDU, China , May 12 /PRNewswire-Asia-FirstCall/ -- Tianyin,Pharmaceutical ... in the modernized traditional Chinese medicine ("TCM") and branded,generics today announced ... , , Third quarter fiscal year 2010 ending ... revenue increased 60% year over year to $15.9 million, net, ...
... This release is available in French . Physicists ... energy involved in adding electrons to semi-conductor nanocrystals, also known ... and other areas of science. Dr. Peter Grtter, McGill,s Associate ... that his research team has developed a cantilever force sensor ...
Cached Biology Technology:Xybion Completes Acquisition of Stelex and Vital-Path, Leaders in Business Process Software and Consulting Services for Regulated Industries, from GE Healthcare 2Xybion Completes Acquisition of Stelex and Vital-Path, Leaders in Business Process Software and Consulting Services for Regulated Industries, from GE Healthcare 3Tianyin Reports Record Third Quarter 2010 Financial Results 2Tianyin Reports Record Third Quarter 2010 Financial Results 3Tianyin Reports Record Third Quarter 2010 Financial Results 4Tianyin Reports Record Third Quarter 2010 Financial Results 5Tianyin Reports Record Third Quarter 2010 Financial Results 6Tianyin Reports Record Third Quarter 2010 Financial Results 7Tianyin Reports Record Third Quarter 2010 Financial Results 8Tianyin Reports Record Third Quarter 2010 Financial Results 9Tianyin Reports Record Third Quarter 2010 Financial Results 10Tianyin Reports Record Third Quarter 2010 Financial Results 11Tianyin Reports Record Third Quarter 2010 Financial Results 12Tianyin Reports Record Third Quarter 2010 Financial Results 13Quantum move toward next generation computing 2
(Date:7/21/2015)... , July 21, 2015  NXT-ID, Inc. (NASDAQ: ... biometric authentication company focused on the growing mobile ... wallet, announces that it has filed provisional patent ... Method. This invention highlights next ... authorizes an account, but also the user using ...
(Date:7/20/2015)... July 20, 2015  Acuity Market Intelligence,s latest ... Convergence of Commerce and Privacy" forecasts that between ... apps will be downloaded to smart mobile devices ... biometrics market is projected to generate more than ... the seven-year forecast period.    "Biometrics ...
(Date:7/13/2015)... , Jul. 13, 2015 NXT-ID, Inc. ... a biometric authentication company focused on the growing ... filed provisional patent 62/188684 for BEHAVIORAL-DIRECTED ... another new convenient and secure method to make ... innovative payment methods, introduced with its groundbreaking voice-direct ...
Breaking Biology News(10 mins):NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 2NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 3NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 4Biometrics on Smart Mobile Devices to Redefine Digital Identity with 12.9 Billion Biometric App Downloads between 2014 and 2020 2NXT-ID Patents Behavior-Directed Payments 2NXT-ID Patents Behavior-Directed Payments 3NXT-ID Patents Behavior-Directed Payments 4
... a species of alfalfa from Siberia, to the United States. His ... But what also happened during this time in the late ... of the matter is creating a current revival in both interest ... And several researchers members of the American Society of Agronomy (ASA) ...
... 31st, 2012.- Madrid will become international destination for ... Innovation Conference 2012, focused on building high performance ... This new organization has been created by the ... Government of the Comunidad de Madrid, through the ...
... CRUZ, CA--Researchers at the University of California, Santa Cruz, ... from wounds and skin infections, using light to trigger ... developed a photoactive compound that releases nitric oxide when ... biocompatible material that could be applied as a sprayable ...
Cached Biology News:Time is ticking for some crop's wild relatives 2MADRID-MIT M+Vision Consortium hosts Biomedical Innovation Conference 2012 2Light-induced delivery of nitric oxide eradicates drug-resistant bacteria 2Light-induced delivery of nitric oxide eradicates drug-resistant bacteria 3
... Unique, compact measuring instrument for calibrating single-channel ... design and the robust carrying case, the ... in the laboratory and on-site at the ... to use because the individual channels are ...
... virus of Japan, also named Sendai virus) ... transfection of molecules by means of membrane ... (RNAi), Protein, Oligo, cDNA, Antibodies, Vector, and ... GenomONE-Neo EX has a high fusing capability ...
... The S. pombe Whole Genome ... location analysis of yeast (S. pombe) ... immunoprecipitation (ChIP) with Agilent DNA microarrays. ... reliable binding data with greater true ...
... This kit is designed for easy transformation ... protocol allows for successful transformation simply by ... reagents with cultured yeast cells. No complicated ... are required. The kit is particularly well ...
Biology Products: